TP Therapeutics, Inc. (TP) is a clinical-stage structure-based oncology drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drug crizotinib and lorlatinib. The TP team is focused on the design and development of novel chemical entities within oncology for established oncogene drivers with high incidence of secondary resistance mutations; newly identified disease-driven targets; and potential targets regulating the tumor microenvironment and tumor immunity. For more information, please visit us at www.tptherapeutics.com. Vice President, Clinical Development (MD Required) ROLE SUMMARY ---------- Jingrong Jean Cui Ph.D.Scientific Founder & Chief Scientific Officer, TP Therapeutics, Inc.
|
| Age | Total Calculated Compensation | This person is connected to 0 Board Member in 0 organization across 1 different industries. |
| -- | -- |
Background
Dr. Jingrong Jean Cui, Ph.D., serves as Scientific Founder and Chief Scientific Officer at TP Therapeutics, Inc. She is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.). Dr. Cui is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®. She created the drug’s novel chemical scaffold based on co-crystal ...
Corporate Headquarters10628 Science Center Drive
San Diego, California 92121 United States Phone: 858-926-5251
Jingrong Jean (崔景榮) CuiFounder, Director, President, and Chief Scientific Officer at TP Therapeutics, Inc.Greater San Diego Area |
